Compare · APRE vs AZN
APRE vs AZN
Side-by-side comparison of Aprea Therapeutics Inc. (APRE) and AstraZeneca PLC (AZN): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both APRE and AZN operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- AZN is the larger of the two at $547.19B, about 55682.4x APRE ($9.8M).
- Over the past year, APRE is down 49.0% and AZN is down 3.9% - AZN leads by 45.2 points.
- APRE has been more active in the news (11 items in the past 4 weeks vs 9 for AZN).
- AZN has more recent analyst coverage (25 ratings vs 5 for APRE).
- Company
- Aprea Therapeutics Inc.
- AstraZeneca PLC
- Price
- $0.85+8.02%
- $180.98+2.60%
- Market cap
- $9.8M
- $547.19B
- 1M return
- -8.20%
- -4.64%
- 1Y return
- -49.05%
- -3.88%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ
- NYSE
- IPO
- 2019
- 2026
- News (4w)
- 11
- 9
- Recent ratings
- 5
- 25
Aprea Therapeutics Inc.
Aprea Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapeutics that reactivate mutant p53 tumor suppressor protein. The company's lead product candidate is APR-246 (Eprenetapopt), a small molecule p53 reactivator that is in late-stage clinical development for the treatment of hematologic malignancies, including myelodysplastic syndromes (MDS) and acute myeloid leukemia, as well as for relapsed/refractory TP53 mutant chronic lymphoid leukemia; and gastric, bladder, and non-small cell lung cancers. It also develops APR-548, a p53 reactivator that is on Phase I dose-escalation clinical trial for oral administration in MDS patients. The company was founded in 2006 and is headquartered in Boston, Massachusetts.
AstraZeneca PLC
AstraZeneca PLC discovers, develops, manufactures, and commercializes prescription medicines in the areas of oncology, cardiovascular, renal and metabolism, respiratory, infection, neuroscience, and gastroenterology worldwide. The company's marketed products include Tagrisso, Lynparza, Imfinzi, Enhertu, Koselugo, Lumoxiti, Equidacent, Zoladex, Faslodex, Iressa, Arimidex, Casodex/Cosudex, and others for oncology diseases; Onglyza, Bydureon, Lokelma, Byetta, Qtern, Symlin, and others for cardiovascular, renal, and metabolism diseases; and Symbicort, Pulmicort, Fasenra, Daliresp/Daxas, Duaklir, Tudorza/Eklira, Bevespi, Breztri, Anifrolumab, and others for respiratory and immunology diseases. It also offers other medicines and COVID-19 products, including Synagis, Fluenz Tetra/FluMist Quadrivalent, Seroquel IR/Seroquel XR, Vimovo, Movantik/Moventig, Nexium, Losec/Prilosec, and COVID-19 Vaccine AstraZeneca. The company serves primary care and specialty care physicians through distributors and local representative offices. It has a collaboration agreement with Daiichi Sankyo to develop and commercialize DS-1062 for the treatment of trophoblast cell-surface antigen 2 (TROP2) tumor; AliveCor, Inc. to develop non-invasive potassium monitoring solutions; Massachusetts General Hospital to accelerate digital health solutions; Sanguina on smartphone application study for hemoglobin management in patients with anemia of chronic kidney disease; Alchemab to enhance prostate cancer research; and Proteros biostructures GmbH to discover and develop novel small molecules for the treatment of various types of cancer. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. It has a collaboration agreement with Regeneron Pharmaceuticals, Inc. to research, develop, and commercialize small molecule medicines for obesity. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom.
Latest APRE
- Next-Generation DNA Repair Therapies Open New Frontiers in Oncology
- Director Grissinger Michael was granted 3,135 shares, increasing direct ownership by 109% to 6,024 units (SEC Form 4)
- Director Gruia Gabriela was granted 3,135 shares, increasing direct ownership by 300% to 4,180 units (SEC Form 4)
- Director Peters Richard was granted 3,135 shares, increasing direct ownership by 101% to 6,254 units (SEC Form 4)
- Director Henneman John B Iii was granted 3,135 shares, increasing direct ownership by 31% to 13,364 units (SEC Form 4)
- Director Bizzari Jean-Pierre was granted 3,135 shares, increasing direct ownership by 300% to 4,180 units (SEC Form 4)
- Director Duey Marc was granted 3,135 shares, increasing direct ownership by 1% to 259,290 units (SEC Form 4)
- Director Pamukcu Rifat was granted 3,135 shares, increasing direct ownership by 58% to 8,581 units (SEC Form 4)
- Director Seizinger Bernd R. was granted 3,135 shares, increasing direct ownership by 7% to 48,910 units (SEC Form 4)
- Aprea Therapeutics Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders
Latest AZN
- Next-Generation DNA Repair Therapies Open New Frontiers in Oncology
- Officer Sharma Mani was granted 1 units of Ordinary Shares, increasing direct ownership by 0.01% to 19,263 units (SEC Form 4)
- SEC Form 6-K filed by AstraZeneca PLC
- TRUQAP® (capivasertib) combination approved in the US as first and only targeted treatment for PTEN-deficient metastatic hormone-sensitive prostate cancer
- NYSE Content Update: AstraZeneca Celebrates Largest Transfer in NYSE History
- Camizestrant Combination Delayed Time to First Progression by 55% and to Second Progression by 37% in Patients With Advanced HR-positive Breast Cancer With an Emergent ESR1 Tumor Mutation in SERENA-6 Trial
- SEC Form 6-K filed by AstraZeneca PLC
- SEC Form 6-K filed by AstraZeneca PLC
- IMFINZI® (durvalumab) plus IMJUDO® (tremelimumab-actl) combined with lenvatinib and TACE reduced the risk of disease progression or death by 30% in embolization-eligible unresectable liver cancer in EMERALD-3 Phase III trial
- SEC Form 6-K filed by AstraZeneca PLC